Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
TACE is an oral small-molecule capsule in pre-launch development by Sanofi under an NDA. The mechanism of action, indication, and therapeutic class remain undisclosed. Patient population cannot be determined without indication data.
Pre-launch stage signals active team building across commercial, regulatory, and medical functions; career growth potential is high but dependent on indication and competitive landscape post-approval.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE
TACE Treats Nodular Goiter
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Worked on TACE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Sanofi is hiring 1 role related to this product
TACE pre-launch status offers career opportunities in launch-phase roles, particularly in regulatory, medical, and commercial strategy. Current job posting volume is zero, but headcount will scale significantly post-approval depending on indication and competitive dynamics.